Besides, lipoproteins containing oxidized phospholipids and fatty acids may contribute to virus-related organ injury by excessively activating innate immune scavenger receptors; restoring lipoprotein function using ApoA-I elevating agents or inhibiting these scavenger receptors with neutralizing antibodies could, therefore, be beneficial in the treatment of COVID-19 (12). This evidence concerns the gene APOA1 and COVID-19.